Introduction
Prostate cancer (PCa) is the second most frequently diagnosed cancer and the sixth leading cause of death in males with cancer worldwide (1) . The most current method for diagnosis for PCa is prostate-specific antigen (PSA) assays (2) . The wide utilization of PSA tests has reduced the death rates of PCa but it has been associated with a high risk of overdiagnosis and overtreatment (3) . Up to 60% of PSA-detected prostate cancer was overdiagnosed (4) . This disadvantage leads to trouble for healthy men and is expensive for patients with benign prostate hyperplasia (BPH) because PSA is a prostate-specific marker only (5) . Thus, the development of additional biomarkers with high sensitivity and specificity for early detection of prostate cancer is vitally necessary.
Aberrant methylation of deoxycytidine nucleotides distributed on CpG islands in promoter sequences is considered as the earliest somatic genome change in cancer; thus, it is a promising marker for cancer diagnosis (6) . In prostate cancer, aberrant DNA methylation frequently occurs at GSTP1 (glutathione S-transferase P1) and RASSF1A (RAS association domain family member 1) genes (7, 8) . GSTP1 protects cells from DNA damage and contributes to cancer initiation (9) . The metaanalysis of GSTP1 methylation in prostate cancer confirmed that GSTP1 methylation is a cancer-specific molecular biomarker for diagnosing prostate cancer with a sensitivity of 82% and a specificity of 95% (10) . The sensitivity and specificity of GSTP1 methylation status in discriminating between PCa and BPH reached 85.5% and 100%, respectively (11) . The measurement of GSTP1 promoter methylation in body fluids showed an excellent specificity, which was much higher than that of PSA for prostate cancer diagnosis (12) . In addition to GSTP1, RASSF1A is a tumor suppressor involved in DNA repair and apoptotic effects (13) . Similar to GSTP1, the metaanalysis indicated that RASSF1A methylation was a potential biomarker in PCa diagnosis and therapy (14) . Aberrant promoter methylation of RASSF1A has been frequently detected (>70%) in prostate cancer, while it was rarely detected in normal tissues (15) . Additionally, RASSF1A is often used in combination with GSTP1 in making a panel of methylation markers to improve sensitivity and specificity of prostate cancer detection (16) . Currently, the methylation status of GSTP1 and RASSF1A is being examined in clinical trials as a promising diagnostic marker of prostate carcinoma (15, 17) .
The highest incidence rates of prostate cancer are in developed countries and the lowest ones are in developing countries (1) . In prostate cancer, DNA methylation of individual genes is also highly divergent between populations (18) . DNA methylation in the promoters of GSTP1 and RASSF1A has extensively been reported in prostate cancer patients in Europe and the United States, but it was rarely reported in patients in Southeast Asian countries. In the present study, we used methylationspecific polymerase chain reaction (MSP) to investigate DNA methylation status of GSTP1 and RASSF1A in benign prostatic hyperplasia and cancerous prostate tissues from Vietnamese patients. Through assessing the methylation status of these two epigenetic markers, the goal of our study was to evaluate their potential as diagnosis biomarkers of prostate cancer in Vietnamese men.
Materials and methods

Prostate tissue samples
Ninety-six formalin-fixed, paraffin-embedded radical prostatectomy patient specimens, including 59 specimens of primary PCa and 37 specimens of BPH, were collected during 2011 and 2012 at the Department of Pathology of National Cancer Hospital K in Hanoi, the largest cancer hospital in Vietnam. The blocks with more than 70% cancerous tissue were selected after histological examination. Clinicopathological characteristics of the patients were obtained from surgical and pathological records. Each tumor was graded according to the Gleason grading system. Informed consent was obtained from the patients via a written form and the study was approved by the guidelines of a local ethics committee in Vietnam. 2.2. Genomic DNA extraction and bisulfite modification Genomic DNA was extracted using a QIAamp DNA FFPE Tissue Kit (QIAGEN) for formalin-fixed paraffin embedded specimens and then treated with sodium bisulfite using an EpiTect Bisulfite Kit (QIAGEN). During the modification, the unmethylated cytosines of the genomic DNA were converted to uracils, but the methylated cytosines remained unchanged (19) . Polymerase chain reaction (PCR) that used globin F/R primers for the native DNA and Un-globin F, R, and R1 for treated DNA (Table 1 ) was performed to Table 1 . MSP primers for analysis of β-globin, GSTP1, and RASSF1A methylation. The lower letters "t" and "a" indicate the unmethylated cytosines that were changed to "t" in the forward primers and to "a" in the reversed primers. determine the efficiency of bisulfite conversion, and PCR that used MSP primers for the native DNA was performed to confirm the primer's specificity only to methylated targets.
Methylation-specific PCR (MSP)
The methylation status of GSTP1 and RASSF1A was evaluated by using MSP for amplification of bisulfitetreated DNA with primers that distinguish methylated (M) from unmethylated (U) DNAs. Based on the primer designing tool for the MSP method (http://www.urogene. org/methprimer/index1.html), the primers for GSTP1 and RASSF1A were designed, and some of these primers were used in combination with the published ones (20) (21) (22) (23) (24) (25) (26) .
The primer sequences and amplicon lengths are shown in Table 1 . Bisulfite-treated DNAs were subjected to single or nested PCR based on particular targeted genes. The PCR products were then subjected to electrophoresis on 12% acrylamide gel. All the PCR reactions were replicated at least three times. DNA that was extracted from the lymphocytes of the healthy volunteers and then treated with bisulfite was used as a positive control for GSTP1 and RASSF1A unmethylation. DNA that was extracted from the PC3 cell line and then treated with bisulfite was used as a positive control for GSTP1 and RASSF1A methylation (27) . Water without a DNA template was included in each PCR reaction as a control for any contamination. The methylation status was confirmed by sequencing the cloned MSP products for a subset of samples from each assay.
Statistical analysis
Associations between clinicopathological characteristics and individual promoter methylation status were examined by using the chi-square test (SPSS Inc., Chicago, IL, USA). For all statistical analyses, P ≤ 0.05 was considered significant.
Results
The population in this study consisted of 59 patients with PCa and 37 patients with BPH, all of whom underwent radical prostatectomy. The clinicopathologic characteristics of all 96 patients are shown in Table 2 . The median age of the cases was 71.65 years (range: 42-91), and most of the cases had tumors with Gleason grade IV or V (41/59 PCa, 69.4%).
Verification of the specificity of MSP primers
Validating the precision of the MSP primers specific only to the methylated target has been recommended in order to avoid false positive results due to coamplification of incompletely converted sequences (28) . Thus, the bisulfite-untreated DNA and the bisulfite-treated DNA were separately subjected to MSP with the GSTP1 and RASSF1A primer sets that were specifically designed for the methylated targets. Efficient amounts of the DNA templates were checked by PCR with the globin primer sets that were designed from the native and unmethylated DNA targets ( Figure 1A) . No MSP products corresponding to the methylated GSTP1 and RASSF1A were amplified from untreated DNA extracted either from PC-3 cells or from the lymphocytes. Similarly, no MSP products corresponding to the methylated targets were amplified from treated DNA extracted from the lymphocytes, which was used as the positive control for unmethylated DNA. The methylated GSTP1 and RASSF1A were detected from only the treated DNA extracted from PC-3 cells ( Figure  1B) . The results confirmed the accuracy of the designed primer sets specific only to the methylated targets. These primers were subsequently subjected to analysis of the methylation status of GSTP1 and RASSF1A in prostate patients. Table 2 . Methylation frequencies of GSTP1 and RASSF1A in the samples of benign hyperplasia (BPH) and prostate cancer (Pca) patients.
Characteristics
Overall, n = 96
GSTP1 RASSF1A
Un, n (%) Me, n (%) P-value Un, n (%) Me, n (%) P-value 
Methylation status of GSTP1 and RASSF1A in PCa and BPH tissues
The genomic DNAs extracted from 59 PCa and 37 BPH specimens were treated with bisulfite and subjected directly to MSP. Representative results of the MSP products for methylation status of GSTP1 and RASSF1A are shown in Figures 2 and 3 , respectively. Three patterns of M/M, M/U, and U/U signals of RASSF1A were observed in both PCa and BPH cases, but these patterns of GSTP1 were observed in cases of PCa only (Table 3) . Biallelic unmethylation (U/U) and monoallelic methylation (M/U) signals of GSTP1 were detected from BPH. Monoallelic M/M and biallelic M/U were count as the methylated status. MSP analysis revealed that the number of the methylated GSTP1 and RASSF1A was 39/59 (66.1%) and 19/59 (32.2%) patients with PCa, respectively ( Table 2 ). MSP analysis also revealed that the methylation of GSTP1 and RASSF1A was detected in 4/37 (10.8%) and 10/37 (27%) patients with BPH, respectively. Forty-three out of 59 PCa (72.9%) samples showed methylation status of one or two genes. 
B2
The DNA methylation frequencies and clinical characteristics corresponding to surgical and pathological records of the cases were compared. There was a significant difference in the methylation rate between PCa and BPH for only GSTP1 (P < 0.01) ( Table 2) . No significant differences in the methylation frequencies of GSTP1 and RASSF1A were observed in terms of age and histological grade (Gleason) of the PCa patients ( Table 2) .
The methylation and unmethylation of GSTP1 and RASSF1A were confirmed by cloning and sequencing MSP products that were amplified from the treated DNAs extracted from the prostate cancer samples (Figure 4) . The nucleotide sequences showed that all cytosine residues were converted to thymidines in the GSTP1 and RASSF1A unmethylated products, and that all cytosines in the CpG sites remained as cytosines and the cytosines that were not in the CpG sites were converted to thymidines in the GSTP1 and RASSF1A methylated products.
Discussion
Among several DNA methylation markers associated with prostate cancer, GSTP1 and RASSF1A methylations captured the most interest because they were strongly associated with and considered as specific molecular biomarkers of prostate cancer (5). Highly significant GSTP1 and RASSF1A methylation rates have been extensively reported from tissue biopsies and body fluids (plasma, serum, whole blood, urine, semen) from patients with prostate cancer (12, 24, 28) This evidence makes them the most promising commercial DNA methylation markers for early detection of this cancer (5) .
DNA methylation profiles of thousands of genes or of a particular gene can be quantitatively assessed by technological approaches such as DNA microarrays or methylation-sensitive high-resolution melting (MS-HRM), which may not be accessible to many institutions in developing countries (29, 30) . The MSP method was chosen in the present study because of its sensitivity, specificity, and suitability in most moderately equipped laboratories (31) . However, false positive results due to MSP primers unspecific to the methylated target have been reported (28) . Thus, the standard controls were set up to test the accuracy of the primers specific to the methylated GSTP1 and RASSF1A through PCR, in which MSP products were amplified neither from the native DNA that was extracted from the lymphocytes or from PC3 cells, nor from the bisulfite-treated DNA that was extracted from the lymphocytes (Figure 1 ). This finding confirmed that the unmethylated targets, as well as a trace of incompletely treated DNA, had not interfered with the MSP results; thus, false positive results were avoided. The MSP result for one gene is dependent on the analyzed sequence of the 5' region; thus, the same nucleotide regions of GSTP1 and RASSF1A promoters that have been previously analyzed by the MSP method were also chosen in the present study (21) (22) (23) (24) 26, 28) . GSTP1 and RASSF1A methylation status of malignant (PCa) and benign (BPH) prostate lesions was elucidated by performing the MSP with the validated primer sets. In a total of 96 patients, 39/59 (66.1%) and 19/59 (32.2%) of PCa cases and 4/37 (10.8%) and 10/37 (27%) of BPH cases were methylated at the GSTP1 and RASSF1A promoters, respectively. A significant difference in GSTP1 methylation rates was only observed between PCa and BPH (P < 0.01) ( Table 3) . This result was consistent with previous reports in which PCa was sensitively and specifically discriminated from BPH based on GSTP1 methylation (11, 21) . The GSTP1 methylation frequency of 66.1% detected in the present study was comparable to that detected in different racial groups. Indeed, the GSTP1 methylation frequency in the same nucleotide region that was analyzed in this study was 90.9%, 73.2%, and 58% from American, Korean, and Indian patients with PCa, respectively (22, 33, 34) . On the contrary, no significant association was observed between RASSF1A methylation status and the clinicopathological parameters from the Vietnamese men who suffered from prostate lesions. In addition, the RASSF1A methylation frequency of 32.2% observed in this study was relatively lower than that detected in other populations, although a similar frequency was found in one other study (34) . The methylation frequency of RASSF1A in Japanese and Pakistan patients, which was analyzed using the MSP method, was 74.0% and 100%, respectively (15, 35) . In a Portuguese population the methylation frequency of RASSF1A was more than 90% as analyzed by the quantitative MSP method (36) . Alternatively, the lower frequency of RASSF1A methylation and unmethylated (lower) sequences. Cytosines in the CpG sites (underlined) remained cytosines in the methylated sequences but they converted to thymidines in the unmethylated ones. All cytosines alone were converted to thymidines in both the methylated and unmethylated sequences.
in this study might be due to the MSP primer's specificity that was validated (Figure 1) . Indeed, false positive results gave rise to an increase of 4 and 2 times the DNA methylation frequency (28) .
A similar frequency of RASSF1A methylation in PCa (32.2%) and in BPH (27%) cases was observed in this study and in previous reports (25, 34) . The occurrence of methylation of RASSF1A in tumor and nontumor tissues from various cancers suggested that it is an early and premalignant sign (37) . Thus, RASSF1A methylation in BPH has been considered as a sign of tumor progression. Indeed, a metaanalysis from 19 published studies on the association between RASSF1A promoter methylation and prostate cancer indicated that RASSF1A methylation was significantly associated with an increased risk of PCa (38) .
Currently, the GSTP1 and RASSF1A methylation in body fluids is extensively studied because of its noninvasive character and its ability to monitor prostate cancer (24, 39) . A high specificity of GSTP1 and RASSF1A methylation was found in these studies, regardless of methylation methods (12, 14) . Thus, the MSP method, which was supported by previous studies and was standardized in this study, is advantageous for further analyzing GSTP1 and RASSF1A methylation in body fluid specimens. Our study emphasized the authentic value of the MSP method that will allow the use of DNA methylation marker to quickly progress toward clinical application, especially in developing countries.
